Lele Song1,2, Shaohua Guo3, Jiayu Wang1,4, Xiumei Peng5, Jia Jia1,4, Yuan Gong6, Bo Yang7, Wenhua Xiao5, Cheng Dong1, Hongyi Liu3, Yuemin Li1. 1. Department of Radiotherapy, the Chinese PLA 309th Hospital, Beijing, PR China. 2. BioChain (Beijing) Science & Techology, Inc., Beijing, PR China. 3. Department of General Surgery, the Chinese PLA General Hospital, Beijing, PR China. 4. Department of Graduate, Hebei North University, Zhangjiakou, Hebei, PR China. 5. Department of Oncology, the First Affiliated Hospital of the Chinese PLA General Hospital, Beijing, PR China. 6. Department of Gastroenterology, the Chinese PLA General Hospital, Beijing, PR China. 7. Department of General Surgery, the Chinese PLA 309th Hospital, Beijing, PR China.
Abstract
AIM: To investigate the performance of methylated SEPT9 (mSEPT9) in assessing the surgical therapeutic effect and prognosis of colorectal cancer (CRC). METHODS: Blood samples before surgery and 1 and 7 days after surgery were obtained from 120 CRC patients, and mSEPT9 and carcinoembryonic antigen (CEA) assays were performed. RESULTS: The mean plasma mSEPT9 level showed 57.6-times and 131.1-times decrease 1 day and 7 days after surgery, respectively. In contrast, mean CEA levels showed 2.51-and 2.70-times decrease 1 and 7 days after surgery. 86.7% of patients can be assessed by mSEPT9 while 44.2% can be assessed by CEA. Positive mSEPT9 detection before surgery correlated with higher risk of death after surgery. CONCLUSION: mSEPT9 is effective for CRC postsurgical assessment and prognosis prediction.
AIM: To investigate the performance of methylated SEPT9 (mSEPT9) in assessing the surgical therapeutic effect and prognosis of colorectal cancer (CRC). METHODS: Blood samples before surgery and 1 and 7 days after surgery were obtained from 120 CRC patients, and mSEPT9 and carcinoembryonic antigen (CEA) assays were performed. RESULTS: The mean plasma mSEPT9 level showed 57.6-times and 131.1-times decrease 1 day and 7 days after surgery, respectively. In contrast, mean CEA levels showed 2.51-and 2.70-times decrease 1 and 7 days after surgery. 86.7% of patients can be assessed by mSEPT9 while 44.2% can be assessed by CEA. Positive mSEPT9 detection before surgery correlated with higher risk of death after surgery. CONCLUSION:mSEPT9 is effective for CRC postsurgical assessment and prognosis prediction.
Authors: Sander Bach; Nina R Sluiter; Jamie J Beagan; Joost M Mekke; Johannes C F Ket; Nicole C T van Grieken; Renske D M Steenbergen; Bauke Ylstra; Geert Kazemier; Jurriaan B Tuynman Journal: JNCI Cancer Spectr Date: 2019-06-19
Authors: Jun Gong; Andrew Hendifar; Alexandra Gangi; Karen Zaghiyan; Katelyn Atkins; Yosef Nasseri; Zuri Murrell; Jane C Figueiredo; Sarah Salvy; Robert Haile; Megan Hitchins Journal: Cancers (Basel) Date: 2021-09-10 Impact factor: 6.639